<< Back To Search

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial

Summary

Third Opinion Trial Synopsis:
This study will test if using belantamab mafodotin with pomalidomide and dexamethasone is better and safer than using pomalidomide, bortezomib, and dexamethasone for people with multiple myeloma that has come back or isn't responding to treatment.
*Third Opinion AI Generated Synopsis

Trial Summary
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?
Contacts: